Compare OMER & WDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMER | WDI |
|---|---|---|
| Founded | 1994 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 844.6M | 715.3M |
| IPO Year | 2008 | N/A |
| Metric | OMER | WDI |
|---|---|---|
| Price | $17.33 | $13.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 211.3K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.80% |
| EPS Growth | ★ 98.15 | N/A |
| EPS | 0.77 | ★ 1.12 |
| Revenue | ★ $29,868,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $233.22 | N/A |
| P/E Ratio | $22.49 | ★ $11.83 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.94 | $12.91 |
| 52 Week High | $18.14 | $15.28 |
| Indicator | OMER | WDI |
|---|---|---|
| Relative Strength Index (RSI) | 83.27 | 49.39 |
| Support Level | $9.12 | $13.00 |
| Resistance Level | $17.65 | $13.86 |
| Average True Range (ATR) | 0.75 | 0.12 |
| MACD | 0.52 | 0.03 |
| Stochastic Oscillator | 87.76 | 83.33 |
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Western Asset Diversified Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income. As a secondary investment objective, the Fund will seek capital appreciation. The fund seeks to achieve its investment objectives by investing, under normal market conditions, across fixed income sectors and securities in seeking to deliver a well-diversified portfolio.